» Articles » PMID: 27059343

Use of Patients With Diarrhea Who Test Negative for Rotavirus As Controls to Estimate Rotavirus Vaccine Effectiveness Through Case-Control Studies

Overview
Journal Clin Infect Dis
Date 2016 Apr 10
PMID 27059343
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Case-control studies are often performed to estimate postlicensure vaccine effectiveness (VE), but the enrollment of controls can be challenging, time-consuming, and costly. We evaluated whether children enrolled in the same hospital-based diarrheal surveillance used to identify rotavirus cases but who test negative for rotavirus (test-negative controls) can be considered a suitable alternative to nondiarrheal hospital or community-based control groups (traditional controls).

Methods: We compared calculated VE estimates as a function of varying values of true VE, attack rates of rotavirus and nonrotavirus diarrhea in the population, and sensitivity and specificity of the rotavirus enzyme immunoasssay. We also searched the literature to identify rotavirus VE studies that used traditional and test-negative control groups and compared VE estimates obtained using the different control groups.

Results: Assuming a 1% attack rate for severe rotavirus diarrhea, a 3% attack rate for severe nonrotavirus diarrhea in the population, a test sensitivity of 96%, and a specificity of 100%, the calculated VE estimates using both the traditional and test-negative control groups closely approximated the true VE for all values from 30% to 100%. As true VE decreased, the traditional case-control approach slightly overestimated the true VE and the test-negative case-control approach slightly underestimated this estimate, but the absolute difference was only ±0.2 percentage points. Field VE estimates from 10 evaluations that used both traditional and test-negative control groups were similar regardless of control group used.

Conclusions: The use of rotavirus test-negative controls offers an efficient and cost-effective approach to estimating rotavirus VE through case-control studies.

Citing Articles

Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan: a test-negative case-control analysis.

Anwari P, Burnett E, Safi N, Samsor A, Safi H, Chavers T Lancet Glob Health. 2024; 12(9):e1517-e1525.

PMID: 39151986 PMC: 11804170. DOI: 10.1016/S2214-109X(24)00237-7.


Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.

Turbyfill C, Adams K, Tenforde M, Murray N, Gaglani M, Ginde A Vaccine. 2022; 40(48):6979-6986.

PMID: 36374708 PMC: 9595377. DOI: 10.1016/j.vaccine.2022.10.034.


Temporal Confounding in the Test-Negative Design.

Dean N, Halloran M, Longini Jr I Am J Epidemiol. 2020; 189(11):1402-1407.

PMID: 32415834 PMC: 7604521. DOI: 10.1093/aje/kwaa084.


Accumulation and Depuration Kinetics of Rotavirus in Mussels Experimentally Contaminated.

Amoroso M, Langellotti A, Russo V, Martello A, Monini M, Di Bartolo I Food Environ Virol. 2019; 12(1):48-57.

PMID: 31691900 DOI: 10.1007/s12560-019-09413-0.


Measuring Rotavirus Vaccine Impact in Sub-Saharan Africa.

Steele A, Groome M Clin Infect Dis. 2019; 70(11):2314-2316.

PMID: 31544209 PMC: 7245150. DOI: 10.1093/cid/ciz918.